

NCIC CLINICAL TRIALS GROUP

GYNECOLOGY

DISEASE SITE COMMITTEE MEETING AGENDA

DELTA CHELSEA HOTEL, TORONTO, ON

APRIL 27, 2012 – 9:00 A.M. - 3:30 P.M.

CHAIRS: MICHAEL FUNG KEE FUNG AND HAL HIRTE

(3:30 P.M. – 4:15 P.M. EXECUTIVE COMMITTEE MEETING – CLOSED)

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

To review aspects of standard care of patients with gynecologic cancer specifically as these practices relate to new NCIC CTG priority initiatives (e.g., ovarian cancer [first line therapy; therapy for platinum resistant disease], cervical cancer)

To review the clinical trials landscape and clinical trials opportunities in Canada

To review the results of recent and ongoing clinical trials in gynecologic oncology and to enhance understandings of the trials' results with respect to intervention adoption.

To summarize recent developments in the understanding of molecular biology and therapeutics as these relate to gynecologic cancers.

-
- 9:00 a.m. **Opening remarks and outline of the meeting** Hirte/FungKeeFung/Meyer
1. Follow up from the last meeting's survey – Road map
 2. Review of the TOR and role of working groups
 3. Building the foundation for success- feedback
 - a) Overview of Gyne Trials landscape and update – Gyne Clinical trial ecosystem blue print
 - b) CCCTN grant
 - c) Role of GOC COP clinical trials group
 - d) Communication between meetings
 - e) Who does what and how can we leverage our combined resources
 - f) CPAC initiative and Gyne Trials groups
 - g) NCIC CTG as the common platform for trial discussion/trial science/scientific issues
 - h) Pathway for trial ideas: where do I go and what are next steps – Clear cell/XRT a case study
 - i) Co-participation of patient interest groups (Mary Manjovich)

10:15 a.m. **BREAK**

10:30 a.m. **New trial ideas for presentations and feedback**

1. Clear cell XRT in ovarian cancer A. Tinker
2. TFRI/COEUR review and input re: data challenges M. Bernardini/
A.M. Mes-Masson

11:00 a.m. **Working group key issues – making it happen**

1. Ovary – OV.21 H. Mackay/D. Provencher
2. Cervix – CX.5 M. Plante/C. Doll
3. Endometrium – EN.7 M. Bernardini/A. Fyles
4. Correlative Studies and Tissue Banking A.M. Mes-Masson

12:00 p.m. **LUNCH**

1:30 p.m. **New understanding of Gyne cancer biology and trial opportunities**

Hirte/Huntsman

2:30 p.m. **Potential new studies**

1. Immunovaccine A. Oza
2. GTN – GOG R. Osborne

3:15 p.m. **Other Updates**

1. NCI US H.Hirte/M. FungKeeFung
2. GCIG H.Hirte/M. FungKeeFung
3. Report on the Committees H.Hirte/M. FungKeeFung

3:30 p.m. **ADJOURN**

Closed meeting of Gyne Executive Council to follow.